Previous clinical trials in hormone receptor-positive (HR+), HER2-negative, node-positive (N+) breast cancer showed that chemotherapy plus hormonal therapy yielded better outcomes than hormonal therapy alone.6–8 In a meta-analysis, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) showed that this benefit of chemotherapy is largely independent of age, nodal status, tumor differentiation, or estrogen receptor (ER) level. Here, ERBB2 is linked to breast cancer.